Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent versus continuous androgen deprivation for prostate cancer in China
ACTRN12613000107729Phase 4Active, not recruiting
- Sponsor
- Changhai Hospital, Second Military Medical University
- Start
- Jan 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of goserelin and bicalutamide in prostate cancer (PCa) (2 arms), sponsored by Changhai Hospital, Second Military Medical University. Primary endpoint: Time to progression. Started Jan 2013; status: active, not recruiting.
02
Drugs
goserelinbicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12613000107729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000107729.